Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $644.7K fell 82.8% year over year, behind the +3.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 71.2% from the prior quarter. Over 3 fiscal years it compounded at -29.6% a year.
Context
- Selling, general & admin amounted to 876.6% of revenue in FY2025.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $39.3M (+228.9%) for the fiscal year ending Dec 2026, a step up from the +77.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $644.7K-71.2% QoQ
- Last fiscal yearDec 2025
- $11.95M+77.7% YoY
- LTMMar 2026
- $8.86M+3.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -82.8% | -1.6% | +81.1 pp |
| 1 year | +77.7% | +228.9% | +151.1 pp |
| 3-year CAGR | -29.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 11.95M USD
- Year-over-year change
- +77.7%
- 4-year CAGR
- -4.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.95M | +77.7% |
| FY2024 | 2024-12-31 | 6.72M | -51.4% |
| FY2023 | 2023-12-31 | 13.82M | -59.6% |
| FY2022 | 2022-12-31 | 34.18M | +142.0% |
| FY2021 | 2021-12-31 | 14.12M | — |
Selling, General & Admin vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 selling, general & admin of $8.86M is the 8th highest of the 9 companies compared; the peer median is $19.19M.
- Its year-over-year change of +3.4% is the 4th highest of 9, against a peer median of -3.7%.
- Selling, general & admin amounts to 626.3% of revenue for COEP, versus a peer median of 334.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.34B | +166786.7% | +2103.6% | — |
| LTM Mar 2026 | $104.54M | -7.7% | -10.2% | 69.2% | |
| LTM Mar 2026 | $38.12M | -1.4% | +24.4% | 11443.7% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Mar 2026 | $16.21M | +11.3% | +0.2% | 49.5% | |
| LTM Mar 2026 | $13.76M | +12.8% | -21.8% | 600.0% | |
| LTM Mar 2026 | $10.46M | -6.1% | -14.5% | — | |
| LTM Mar 2026 | $8.86M | +3.4% | -29.6% | 626.3% | |
| LTM Mar 2026 | $6.83M | -36.5% | +628.7% | — | |
| Peer median (excluding COEP) | $19.19M | -3.7% | -4.4% | 334.6% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| Weighted Avg Shares | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
| Weighted Avg Shares (Diluted) | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.